gyrA mutations in ciprofloxacin-resistant clinical isolates of Pseudomonas aeruginosa in a Silesian Hospital in Poland

Polish Journal of Microbiology

Volumn 54, Issue 3, 2005, Pages 201-206

  Wydmuch, Zenobia ^a   Skowronek Ciołek, Olga ^a   Cholewa, Krzysztof ^a   Mazurek, Urszula ^a   Pacha, Jerzy ^a   Kȩpa, Małgorzata ^a   Idzik, Danuta ^a   Wojtyczka, Robert D ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Ciprofloxacin; gyrA; Mutation; Pseudomonas aeruginosa; Resistance

Indexed keywords

CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; CONTROLLED STUDY; DNA SEQUENCE; GENE MUTATION; HOSPITAL; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PENNSYLVANIAN (EPOCH); POLAND; PSEUDOMONAS AERUGINOSA; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

AMINO ACID SEQUENCE; ANTI-BACTERIAL AGENTS; BASE SEQUENCE; CIPROFLOXACIN; DNA GYRASE; DNA, BACTERIAL; DRUG RESISTANCE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; MUTATION; POLAND; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; SEQUENCE ALIGNMENT;

BACTERIA (MICROORGANISMS); PSEUDOMONAS AERUGINOSA;

EID: 25844525687     PISSN: 17331331     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Akasaka T., M. Tanaka, A. Yamaguchi and K. Sato. 2001. Type II topoisomerase mutations in fluoroquinolone-resistant clinical strains Pseudomonas aeruginosa isolated in 1998 and 1999: role of target enzyme in mechanism of fluoroquinolone resistance. Antimicrob. Agents Chemother. 45: 2263-2268.
2. Ball P. 1994. Bacterial resistance to fluoroquinolones: lessons to be learned. Infection 22: 140-147.
3. Bearden D.T. and L.H. Danziger. 2001. Mechanism of action and of resistance to quinolones. Pharmacotherapy. 21: 224S-232S.
4. Drilica K. and X. Zhao. 1997. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol. Mol. Biol. Rev. 61: 377-392.
5. Kureishi A., J.M. Diver, B. Beckthold, T. Schollaardt, L.E. Bryan. 1994. Cloning and nucleotide sequence of Pseudomonas aeruginosa DNA gyrase gyrA gene from strain PAO1 and quinolone-resistant clinical isolates. Antimicrob. Agents Chemother. 38: 1944-1952.
6. Mouneimné H., J. Robert, V. Jarlier and E. Cambau. 1999. Type II topoisomerase mutations in ciprofloxacin-resistant strains of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 43: 62-66.
7. Nakajima A., Y. Sugimotoo, H. Yoneyama and T. Nakae. 2002. High-level fluoroquinolone resistance in Pseudomonas aeruginosa due to interplay of the MexAB-OprM efflux pump and the DNA gyrase mutation. Microbiol. Immun. 46:391-395.
8. Nakano M., T. Deguchi, T. Kawamura, M. Yasuda, M. Kimura, Y. Okano and Y. Kawada. 1997. Mutations in the gyrA and parC genes in fluoroquinolone-resistant clinical isolates of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 41: 2289-2291.
9. National Committee for Clinical Laboratory Standards. 2000. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 5th edn. Approved standard. NCCLS document M7-A5. Wayne, Pennsylvania.
10. Takenouchi T., E. Sakagawa, M. Sugawara. 1999. Detection of gyrA mutations among 335 Pseudomonas aeruginosa strains isolated in Japan and their susceptibilities to fluoroquinolones. Antimicrob. Agents Chemother. 43: 406-409.
11. Weigel L.M., Ch.D. Steward and F.C. Tenover. 1998. gyrA mutations associated with fluoroquinolone resistance in eight species of Enterobacteriaceae. Antimicrob. Agents Chemother. 42: 2661-2667.
12. Yonezawa M., M. Takahata, N. Matsubara, Y. Watanabe and H. Narita. 1995. DNA gyrase gyrA mutations in quinolone-resistant clinical isolates of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 39: 1970-1972.
13. Yoshida H., M. Bogaki, M. Nakamura and S. Nakamura. 1990. Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli. Antimicrob. Agents Chemother. 34: 1271-1272.